FindTrial
Sign In

Prognostic value of MBP and Spectrin breakdown products on the neurological outcome in patients after cardiac arrest: A prospective cohort study

Prognostic value of MBP and Spectrin breakdown products on the neurological outcome in patients after cardiac arrest: A prospective cohort study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800020128
Enrollment
Unknown
Registered
2018-12-15
Start date
2018-11-01
Completion date
Unknown
Last updated
2018-12-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neural dysfunction after cardio-pulmonary resuscitation

Interventions

Gold Standard:Cerebral performance category (CPC) score: CPC 1 = good cerebral performance, CPC 2 = moderate cerebral disability
CPC 3 = severe cerebral disability, but conscious
CPC 4 = coma
CPC 5 = death.
Index test:MBP&#32
and&#32
Spectrin&#32
breakdown&#32
products

Sponsors

The Fifth People's Hospital of Dongguan
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged ?18 years; 2. Cardiac arrest was defined as receipt of chest compressions for pulselessness by a healthcare worker; 3. Return to spontaneous circulation after cardio-pulmonary resuscitation.

Exclusion criteria

Exclusion criteria: Patients with chronic (such as epilepsy, neural tumor)or acute (such as tramatic brain injury, cerebral hemorrhage) neural organic diseases were excluded.

Design outcomes

Primary

MeasureTime frame
MBP;Spectrin breakdown products;—

Countries

China

Contacts

Public ContactChen Yi

The Fifth People's Hospital of Dongguan

6054618@qq.com+86 13580538400

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026